NS |SECTOR:
PHARMACEUTICALS
Q1 FY16 Recap
Scale up of two new APIs Lurasidone(anti-psychotic) and
Rivaroxaban(anti-coagulant)
Significant progress in one of
the CMS products with NDA
being filed in the US market
Key Molecules
Ciprofloxacin, Salmeterol,
Mirtazapine, Enalapril Maleate,
Sotalol Hcl, Levetiracetam,
Entacapone, Levofloxacin and
several NCE molecules
Regulatory Accreditations
USFDA,EDQM (Europe),EMA
(Europe), PMDA (Japan),TGA
(Australia), BfArM (Germany),
AFSSAPS (France), ANVISA
(Brazil),COFEPRIS (Mexico) and
KFDA (South Korea)
Q3 | FY 2015
Sucheth Davuluri,
CEO, Neuland Labs
Q2FY16
Q2FY15
1,195.9
1,196.8
75.0
16.4
1,271.0
1,213.1
669.7
692.9
10.9
YOY%
Q1FY16
QOQ%
H1FY16
H1FY15
QOQ%
1,151.5
2,347.4
2,195.2
74.8
149.8
44.6
2,497.3
2,239.9
670.0
1,339.8
1,329.7
(10.3)
(37.5)
(26.7)
(102.5)
122.8
122.8
130.9
253.7
228.2
39.0
39.0
38.0
77.0
78.0
140.3
160.0
144.4
284.7
284.2
142.9
93.9
118.3
261.3
210.4
1,125.6
1,098.2
1,064.2
2,189.8
2,027.9
145.4
114.9
307.5
212.0
10.6
23.2
26.8
30.5
156.0
138.1
334.3
242.5
Finance Costs
62.8
63.0
128.2
119.8
93.2
75.1
206.1
122.7
PBT
93.2
75.1
206.1
122.7
Tax Expense
31.2
23.6
71.1
41.0
PAT
62.0
51.5
135.0
81.7
89.5
77.3
89.5
77.3
6.98
6.21
12%
8.22
-15%
15.20
9.76
56%
6.98
6.21
12%
8.22
-15%
15.20
9.76
56%
5%
1,226.3
4%
11%
Expenses
Total Expenses
EBIT Before Other Income / Exceptional
Items
Other Income
EBIT Before Exceptional Items
Exceptional Item
27%
162.2
-10%
16.2
13%
178.3
-13%
65.4
24%
112.9
-17%
24%
112.9
-17%
39.9
21%
73.0
-15%
89.5
45%
38%
68%
68%
65%
H1FY16
FY15
89.5
89.5
1,643.4
1,508.7
1,732.9
1,598.3
298.9
332.2
105.0
122.5
27.3
27.3
69.7
63.8
500.9
545.8
1,367.4
1,458.0
1,234.3
1,139.7
274.8
309.5
85.0
60.4
2,961.5
2,967.6
5,195.4
5,111.7
1,668.6
1,645.4
76.7
76.7
204.9
238.3
1,950.2
1,960.4
(a) Inventories
1,221.0
1,134.0
1,273.7
1,288.5
120.5
64.9
460.6
488.7
169.4
175.2
3,245.2
3,151.3
5,195.4
5,111.7
TOTAL
Assets
(1) Non-current assets
(a) Fixed assets
(b) Non-current investments
(c) Long-term loans and advances
Total
If you have any questions or require further information, please feel free to
contact
Neuland Labs
Anil Kumar
Chief Financial Officer
Tel: +91 40 3021 1600
anilkumar@neulandlabs.com
US Contact
Jenna Palmieri
Neuland Laboratories Inc.
jenna@neulandlabs.com
IR Partner
Ankit Gupta
Christensen
Tel : +91 22 4215 0210
ankitgupta@christensenir.com
Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject
to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other
factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company
will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forwardlooking statements to reflect subsequent events or circumstances.